Helicobacter最新文献

{"title":"Gankyrin Inhibition Can Control Helicobacter pylori Generated Gastric Cancer Using In Vivo Xenograft Models","authors":"Dharmendra Kashyap,&nbsp;Pranit Hemant Bagde,&nbsp;Siddharth Singh,&nbsp;Nidhi Varshney,&nbsp;Tarun Prakash Verma,&nbsp;Anamika Singh,&nbsp;Hamendra Singh Parmar,&nbsp;Hem Chandra Jha","doi":"10.1111/hel.70046","DOIUrl":"https://doi.org/10.1111/hel.70046","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Gastric cancer (GC) is a leading cause of cancer-related mortality worldwide, with <i>Helicobacter pylori</i> (<i>H. pylori</i>) infection recognized as a significant risk factor. <i>H. pylori</i> infects approximately 50% of the global population, contributing to chronic gastritis, peptic ulcers, and the development of GC. The oncoprotein Gankyrin (PSMD10) has been implicated in various human cancers, including hepatocellular carcinoma, gastric cancer, and lung cancer, by modulating autophagy and inflammatory pathways.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this study, we explored the role of Gankyrin in <i>H. pylori</i>-induced gastric tumorigenesis via a Swiss albino mouse xenograft model. Mice were subcutaneously injected with <i>H. pylori</i>-infected AGS cells with or without Gankyrin knockdown.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We assessed tumor growth and inflammatory markers (TNF-α and IL-6) levels and Gankyrin's downstream signaling molecules (p53, pRb, and NF-κB). Our results demonstrated that Gankyrin knockdown significantly decreased tumor formation in Swiss albino mice engrafted with <i>H. Pylori</i>-infected AGS cells. Notably, treatment with cyclosporine A significantly decreased the expression of TNF-α in all the AGS-engrafted mice except the PBS group. Moreover, our results show that the downregulation of Gankyrin significantly elevated the expression of NF-κB, pRb, and p53.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings suggest that Gankyrin plays a crucial role in <i>H. pylori</i>-mediated GC progression by modulating inflammatory and tumor suppressor pathways. Targeting Gankyrin could provide a therapeutic strategy to mitigate the development of GC associated with <i>H. pylori</i> infection.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Capabilities of Novel Open-Source Artificial Intelligence—DeepSeek in Helicobacter pylori-Related Queries","authors":"Ren-Chun Du,&nbsp;Yu-Chen Zhu,&nbsp;Yu-Tian Xiao,&nbsp;Bei-Ning Yang,&nbsp;Yong-Kang Lai,&nbsp;Zhi-Xiang Zhou,&nbsp;Hao Deng,&nbsp;Xu Shu,&nbsp;Nong-Hua Lu,&nbsp;Yin Zhu,&nbsp;Yi Hu","doi":"10.1111/hel.70045","DOIUrl":"https://doi.org/10.1111/hel.70045","url":null,"abstract":"","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Therapeutic Outcomes Between Concomitant Therapy and Tailored Therapy for Helicobacter pylori: A Multicenter, Prospective, and Randomized Study","authors":"Young Sin Cho,&nbsp;Sun Moon Kim,&nbsp;Sun Hyung Kang,&nbsp;Hee Seok Moon,&nbsp;Jae Kyu Sung,&nbsp;Ki Bae Bang,&nbsp;Sung Hyeok Ryou,&nbsp;Ki Bae Kim,&nbsp;Hae Joung Sul,&nbsp;Seung-Woo Lee","doi":"10.1111/hel.70040","DOIUrl":"https://doi.org/10.1111/hel.70040","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The increasing trend of clarithromycin resistance in <i>Helicobacter pylori</i> (<i>H. pylori</i>) is the primary cause of failure of standard triple therapy. Concomitant therapy is recommended as an alternative in regions with high rates of clarithromycin resistance. Recently, tailored therapies based on resistance testing have emerged as viable treatment approaches. We aimed to compare the eradication rates and adverse effects of concomitant and tailored therapies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>We enrolled 319 patients diagnosed with <i>H. pylori</i> infection using dual-priming oligonucleotide (DPO) polymerase chain reaction (PCR) tests conducted in six hospitals across the Daejeon and Chungcheong regions of Korea. Based on DPO-PCR results, patients were randomly assigned to either the concomitant therapy group (non-bismuth quadruple therapy) or the tailored therapy group (standard triple therapy for clarithromycin-sensitive cases and bismuth quadruple therapy for clarithromycin-resistant cases). Demographics, eradication success rates, adverse effects, and patient compliance were assessed. Data were analyzed using modified intention-to-treat (mITT) and per-protocol (PP) analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The eradication rate was significantly higher in the tailored therapy group than in the concomitant therapy group in PP analysis (92.62% vs. 85.21%, <i>p</i> = 0.026). The severity of adverse effects was significantly greater in the concomitant therapy group than in the tailored therapy group (<i>p</i> = 0.025).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Considering the high eradication success rate and low severity of adverse effects, tailored therapy based on DPO-PCR is preferable to concomitant therapy without resistance testing for the treatment of <i>H. pylori</i> infection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>Clinical Research Information Service (CRIS): KCT0004162</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144108801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Efficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication: A Systematic Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis”","authors":"","doi":"10.1111/hel.70044","DOIUrl":"https://doi.org/10.1111/hel.70044","url":null,"abstract":"<p>V. Mishra, D. Dash, A. K. Panda, et al., “Efficacy of <i>Lactobacillus</i> spp. Supplementation in <i>Helicobacter pylori</i> Eradication: A Systematic Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis,” Helicobacter 29, no. 6 (2024): e70006, doi: https://doi.org/10.1111/hel.70006.</p><p>In the Abstract, Results (Sections 3.3–3.4), and GRADE evidence profile (Table 1), the risk ratio (RR) 95% CI values were mistakenly reported from Egger's regression 95% CI values (Table S3). Below, we provide a table of actual 95% CI values for RR as reported in the Forest plots (Figures 1–4).</p><p>We apologize for this error.</p>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hel.70044","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144074359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply: Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First-Line Helicobacter pylori Eradication Treatment More Effective? A Three-Arm, Multicenter Randomized Clinical Trial","authors":"Xinlu Ren,&nbsp;Zhiqiang Song","doi":"10.1111/hel.70043","DOIUrl":"https://doi.org/10.1111/hel.70043","url":null,"abstract":"","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143938992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of Fecal Microbial Communities in Patients With Type 2 Diabetes Mellitus Combined With Helicobacter pylori Infection","authors":"Xiaoyan He,&nbsp;Han Chen,&nbsp;Fengdan Chen,&nbsp;Wei Su,&nbsp;Yan Wang,&nbsp;Die Hu,&nbsp;Jianwen Hu,&nbsp;Xiaoying Zhou","doi":"10.1111/hel.70041","DOIUrl":"https://doi.org/10.1111/hel.70041","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p><i>Helicobacter pylori</i> (<i>H. pylori</i>) infection has the capacity to alter the gut microbiota composition. There is a significant correlation between <i>H. pylori</i> infection and type 2 diabetes mellitus (T2DM). Further research is necessary to explore whether gut microbiota plays a role in the relationship between <i>H. pylori</i> and T2DM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>Fecal samples were obtained from 44 patients with T2DM, including 20 who tested positive for <i>H. pylori</i> and 24 who tested negative. Intestinal microbiota composition was analyzed via 16S rRNA V3-V4 amplicon sequencing. Differences in microbial distribution and significant microbial biomarkers were identified between <i>H. pylori</i> positive and negative groups. A Spearman correlation analysis assessed the relationship between intestinal microbiota and glycemic parameters. Additionally, PICRUSt2 was used to predict intestinal bacterial functions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Results indicate that in <i>H. pylori</i> (+) T2DM patients, HbA1c levels were significantly higher (8.9% vs. 8.1%, <i>p</i> = 0.021), while both the C-peptide peak (3.70 vs. 5.98 ng/mL, <i>p</i> = 0.040) and fasting C-peptide levels (1.42 vs. 2.31 ng/mL, <i>p</i> = 0.008) were significantly lower compared to <i>H. pylori</i> (−) T2DM groups. A total of 11 colonic phyla and 100 genera were identified in all fecal samples. In groups positive for <i>H. pylori</i>, there was a significant enrichment of the phylum <i>Proteobacteria</i>, while the genera <i>Lactobacillus</i>, <i>Butyricimonas</i>, and <i>Akkermansia</i> were significantly reduced (all <i>p</i> &lt; 0.05). Correlation analysis showed that the abundance of the genera <i>Butyricimonas</i> (<i>p</i> = 0.01) and <i>Akkermansia</i> (<i>p</i> = 0.048) were negatively correlated with fasting plasma glucose. KEGG pathway analysis indicated a significant enrichment of methylmalonyl-CoA mutase and succinyl-CoA in <i>H. pylori</i>-infected T2DM patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study suggests that T2DM patients with <i>H. pylori</i> infection exhibit more impaired pancreatic islet function potentially due to <i>H. pylori</i>-induced alterations in the gut microbiota.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143919319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Optimal Age of Helicobacter pylori Screen-and-Treat for Gastric Cancer Prevention in the United States","authors":"Duco T. Mülder,&nbsp;James F. O'Mahony,&nbsp;Dianqin Sun,&nbsp;Luuk A. van Duuren,&nbsp;Rosita van den Puttelaar,&nbsp;Matthias Harlass,&nbsp;Weiran Han,&nbsp;Robert J. Huang,&nbsp;Manon C. W. Spaander,&nbsp;Uri Ladabaum,&nbsp;Iris Lansdorp-Vogelaar","doi":"10.1111/hel.70039","DOIUrl":"https://doi.org/10.1111/hel.70039","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Recent American College of Gastroenterology (ACG) guidelines recommend screening and eradicating <i>Helicobacter pylori</i> (<i>H. pylori</i>) in high-risk racial groups to prevent gastric cancer (GC), but do not provide guidance on the age to screen. We aimed to determine the optimal age for <i>H. pylori</i> screen-and-treat.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>We developed a new microsimulation model, MISCAN-gastric, which was calibrated to SEER incidence and clinical studies on the natural history of GC. One-time screen-and-treat at ages 20–65 was compared to a no-screening scenario in terms of cumulative incidence reduction, number needed-to-screen (NNS) and number needed-to-treat (NNT) to prevent one GC case. The NNS represents the number of individuals that require testing to prevent one GC case, while the NNT reflects the number requiring treatment. The optimal age was investigated for a high-risk population subgroup (non-Hispanic [NH] Black males) and compared to other subgroups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Without screening, 332 noncardia GC cases occurred in a population of 100,000 NH Black males. <i>H. pylori</i> screen-and-treat reduced cumulative incidence by 43% when performed at age 20, but only by 5% when performed at age 65. The NNS was lowest at age 30 and increased markedly at older ages. The estimated NNS for test-ages 20, 30, 40, and 65 were 645, 563, 769, and 5487, respectively. The NNT was lowest at the youngest age (261) and increased with age to 448 at age 40 and 3681 at age 65. The NNT and NNS were substantially higher in groups with lower GC risk: the optimal NNT was four times higher in NH White females compared to non-Hispanic Black males.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p><i>H. pylori</i> screen-and-treat maximized population benefits when performed before age 40, emphasizing the need for early interventions. When performed at the optimal age, the benefits of <i>H. pylori</i> screen-and-treat may outweigh the harms for high-risk racial groups.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hel.70039","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143914519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HIF-1α-Induced GPR171 Expression Mediates CCL2 Secretion by Mast Cells to Promote Gastric Inflammation During Helicobacter pylori Infection","authors":"Hanmei Yuan,&nbsp;Yuetong Li,&nbsp;Hui Wu,&nbsp;Jin Zhang,&nbsp;Tingting Xia,&nbsp;Bin Li,&nbsp;Chao Wu","doi":"10.1111/hel.70042","DOIUrl":"https://doi.org/10.1111/hel.70042","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p><i>Helicobacter pylori</i> (<i>H. pylori</i>) infection is one of the most important risk factors for chronic gastritis, gastric ulcers, and gastric cancer. Mast cells act as a crucial regulator in bacterial infection. The mechanisms underlying mast cell activation and their role in <i>H. pylori</i> infection remain poorly understood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>In gastric mucosal tissue, the number of mast cells, G-protein-coupled receptor 171 (GPR171) and CCL2 expression were detected by immunohistochemistry (IHC) or immunofluorescence between <i>H. pylori</i>-negative and <i>H. pylori</i>-positive patients. Mast cells were co-cultured with <i>H. pylori</i>, and transcriptome sequencing, RT-qPCR, and Western blotting (WB) were performed to identify receptors involved in mast cell activation. WB, chromatin immunoprecipitation (ChIP), and dual-luciferase reporter assays were conducted to investigate the molecular mechanism by which HIF-1α regulates GPR171 expression. Lentiviral knockdown, ELISA, WB, and IHC were used to evaluate the role of GPR171 during <i>H. pylori</i> infection. An in vivo mouse model of <i>H. pylori</i> infection was employed to assess the effects of GPR171 blockade on CCL2 expression and gastric mucosal inflammation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the study, we found that mast cell numbers were greatly increased and correlated with the severity of inflammation in <i>H. pylori-</i>infected patients. We found a new receptor, GPR171, was upregulated and involved in mast cell activation upon <i>H. pylori</i> infection. Furthermore, <i>H. pylori</i> infection induced the expression of GPR171 by promoting the activation of hypoxia-inducible factor 1 alpha (HIF-1α), which directly bound to hypoxia response elements in the GPR171 promoter and regulated its transcriptional activity. Blockade or loss of GPR171 in mast cells partially inhibited CCL2 secretion via the ERK1/2 signaling pathway. In the human gastric mucosa, CCL2 derived from mast cells was associated with gastric inflammation during <i>H. pylori</i> infection. In vivo murine studies indicated that <i>H. pylori</i> infection significantly upregulated CCL2 expression, while GPR171 inhibition partially reduced CCL2 levels and alleviated gastric mucosal inflammation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We provide a novel mechanism that <i>H. pylori</i> activates mast cells to promote gastric inflammation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hel.70042","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143905010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seven-Day Versus 14-Day Tegoprazan and Tetracycline-Containing Quadruple Therapy for First-Line Eradication of Helicobacter pylori Infection: A Randomized, Open-Label, Noninferiority Trial","authors":"Xue-Ping Nan,&nbsp;Hong-Yu Zhao,&nbsp;Lei-Na Guo,&nbsp;Rui-Qi Zheng,&nbsp;Xi-Lan Wang,&nbsp;Yong-Fen Wang,&nbsp;Yan-Hua Su,&nbsp;Wen-Rong Geng,&nbsp;Xiu-Lan Liu,&nbsp;Hai-Miao Xu,&nbsp;Ke-Lun Zhou,&nbsp;Yu-Ting Guo,&nbsp;Jian-Hua Cao,&nbsp;Zhong-Xue Han,&nbsp;Qing-Zhou Kong,&nbsp;Xiu-Li Zuo,&nbsp;Yan-Qing Li,&nbsp;Yue-Yue Li","doi":"10.1111/hel.70036","DOIUrl":"https://doi.org/10.1111/hel.70036","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Tegoprazan, a new class of drugs, is a potassium-competitive acid blocker (P-CAB) that inhibits gastric H+/K+-ATPase through a different mechanism than proton pump inhibitor. Tetracycline also has anti-<i>Helicobacter pylori</i> properties. However, only a few randomized controlled trials (RCTs) have investigated the efficacy of tegoprazan and tetracycline-containing quadruple therapy (TTQT) for treating <i>H. pylori</i> infections, which this RCT explored.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This multicenter RCT included treatment-naïve adults with <i>H. pylori</i> infection who received 7 or 14 days of TTQT (50-mg tegoprazan, 220-mg bismuth potassium citrate, and 1000-mg amoxicillin twice daily with 500-mg tetracycline four times daily). The primary outcome was the eradication rate; secondary endpoints included the incidence of adverse events, treatment compliance, and regimen costs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study included 258 patients. The eradication rates in the 7- and 14-day groups were 90.70% (117/129, 95% confidence interval [CI]: 83.98%–94.89%) and 91.47% (118/129, 95% CI: 84.90%–95.45%), respectively, in the intention-to-treat analysis (difference: −0.78%; −7.01%–8.58%; noninferiority <i>p</i> &lt; 0.001); 92.86% (117/126, 95% CI: 86.50%–96.48%) and 93.65% (118/126, 95% CI: 87.47%–97.02%), respectively, in the modified intention-to-treat analysis (difference: 0.79%; 95% CI: −6.36%–7.99%; noninferiority <i>p</i> &lt; 0.001); and 94.35% (117/124, 95% CI: 88.29%–97.50%) and 95.12% (117/123, 95% CI: 89.24%–98.00%), respectively, in the per-protocol analysis (difference: −0.77%; 95% CI: −5.91%–7.48%; noninferiority <i>p</i> &lt; 0.001). Significantly fewer adverse events occurred in the 7-day group than in the 14-day group (22.48% vs. 35.67%, <i>p</i> = 0.020). Treatment compliance did not differ between the two groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The 7- and 14-day TTQT efficacies for the first-line treatment of <i>H. pylori</i> infection were comparable, and fewer adverse effects occurred in the 7-day group. This trial has been registered at Clinical Trials.gov (NCT05997433).</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143865876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Cefuroxime-Based Dual Therapy With Quadruple Therapy in Helicobacter pylori-Infected Treatment-Naive Patients: A Prospective, Multicenter, Randomized Controlled Trial","authors":"Ji-Yan Li,&nbsp;Ji-Chun Song,&nbsp;Xia Tian,&nbsp;Yun-Hua Liu,&nbsp;Xiang-Wu Ding,&nbsp;Ya Lin,&nbsp;Zhen-Yu Zhang,&nbsp;Hai Zhang,&nbsp;De-Min Li,&nbsp;Xiao-Wei Huang,&nbsp;Yun-Lian Hu,&nbsp;Li Li,&nbsp;Hong-Tian Li,&nbsp;Chao-Qun Huang,&nbsp;Pei-Yuan Li","doi":"10.1111/hel.70037","DOIUrl":"https://doi.org/10.1111/hel.70037","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>High-Dose Dual Therapy With Amoxicillin Has Shown Advantages to Eradicate <i>Helicobacter pylori</i> (<i>H. pylori</i>), but Not for Penicillin-Allergic Patients. It Is Recommended That Cefuroxime Could Be an Alternative, but Whether Cefuroxime Could Be Used in Dual Therapy Has Not Been Reported. This Study Aimed to Compare the Efficacy, Safety, and Compliance of Cefuroxime-Based Dual Therapy (CDT) With Cefuroxime-Based Bismuth Quadruple Therapy (CQT) to Treat <i>H. pylori</i> Infection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>The Prospective, Multicenter, Open-Label, Randomized Controlled Trial Was Conducted to Enroll Patients With Treatment-Naive <i>H. pylori</i> Infection From 9 Institutions. Patients Were Randomly Assigned to CDT Group (Cefuroxime 500 Mg Three Times/Day and Vonoprazan 20 Mg Twice/Day) or CQT Group (Cefuroxime 500 Mg Twice/Day, Levofloxacin 500 Mg Once/Day, Vonoprazan 20 Mg Twice/Day, and Bismuth 220 Mg Twice/Day), both for 14 Days.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>700 Patients (350 per Group) Were Enrolled. In the Intention-To-Treat Analysis, Eradication Rates Were 76.0% and 86.3% in CDT Group and CQT Group (<i>P</i> = 0.001). In the Modified Intention-To-Treat Analysis, Eradication Rates Were 78.9% and 89.1% (<i>P</i> &lt; 0.001). In the Per-Protocol Analysis, Eradication Rates Were 80.2% and 91.2% (<i>P</i> &lt; 0.001). The Incidence of Adverse Events Was Significantly Lower in CDT Group Than CQT Group (14.4% vs. 29.8%, <i>P</i> &lt; 0.001). Non-inferiority Was Confirmed Between CDT and CQT Group (All <i>P</i> &gt; 0.025). Compliance Was Good in Both Groups (96.0% vs. 92.8%, <i>P</i> = 0.073). Poor Adherence Was a Risk Factor for Reducing the Efficacy in Both Groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>CQT Was More Effective Than CDT for <i>H. pylori</i> Eradication, Which Might Be Recommended for Penicillin-Allergic Patients. If There Were Contraindications or Intolerance of CQT, CDT Would Be an Alternative.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trail Registration</h3>\u0000 \u0000 <p>ChiCTR2300071210</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143845827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}